第三届地坛国际感染病会议——国际肝病-打造专业的肝病学术网站

会议简介

[BJDITAN09]...第三届地坛国际感染病会议暨感染病领域的全球对话于7月30～8月2日在北京国际会议中心圆满举行。本次会议有1000余人注册，其中国外参会者200余人。大会特邀国际感染病学会主席Raul E. Isturiz、欧洲感染病学会主席Giuseppe Cornaglia、欧洲肝病学会主席Heiner Wedemeyer；国内感染病学和肝病学专家庄辉院士、贾继东教授、魏来教授等出席。查看详细>>

点击排行

资源统计

热点聚焦

[BJDITAN09]免疫缺陷患者慢性HBV感染的管理
Lamivudine has been approved to be effective and safe in the management of immunosuppressive patients， other nucleoside analogues (telbivudine， entecavir) or nucleotide analogues (adefovir dipivoxil， tenofovir) are potential candidates in this situation， but larger experiences are yet missing.
[BJDITAN09]The Role of HBV Viral Quasispecies in HBeAg Seroconversion
Conclusion: The gradual increase of HBV quasispecies over time before HBeAg seroconversion could be related to accumulation of stochastic mutations which result in occurrence of new CpG motifs that activated the innate immune response and break the immune tolerance leading to HBeAg seroconversion.
[BJDITAN09]乙肝复燃时I型干扰素的免疫学作用：干扰素如何抗HBV
Overall， IFNa treatment is associated with a reduced virion productivity. To what extent this due to direct intracellular mechanisms or deletion of HBV-infected cells remains to be determined. Future studies will have to define in more detail which patients are good candidates of IFNa treatment and ...
[BJDITAN09]性别和HBV—人类性激素和HBV转录-复制之间的相互作用
One interesting outcome of chronic hepatitis B virus infection has been a more common development of end-stage liver diseases in males than females. This gender disparity is more striking in HBV-related liver cancer， in which male patients usually outnumber females to 5-7 folds.
[BJDITAN09]Clostridium difficile Infections
Currently, Clostridium difficile rivals methicillin-resistant Staphylococcus aureus (MRSA) as the most common organism to cause healthcare-associated infections in the United States. Incidence of C. difficile infection (CDI) has also increased in Canada, Europe, and other parts of the world. CDI is ...
[BJDITAN09]慢性丙肝应答指导的治疗
Pegylated interferon alfa in combination with ribavirin administered for 48 and 24 weeks has been approved as standard antiviral treatment in patients with HCV genotype 1 (4-6) and 2/3 infection， respectively， in many countries. Different virusand host-related baseline parameters are known to predic...
[BJDITAN09]基因1、2型丙肝患者血脂情况对HCV RNA的影响
Chronic hepatitis C virus (HCV) infection， a leading cause of cirrhosis， hepatocellular carcinoma (HCC) and liver failure， affects more than 170 million people worldwide. Despite the improving sustained virologic response (SVR) rates with the currently approved interferon-based therapies， these ther...
[BJDITAN09]Management of Hepatitis C Patients and Prevention of HCC
Anti-viral for HCC: It could be assumed that the anti-viral could be only for prevention. However, our data clearly indicated that the eradication of HCV in patients who already developed HCC were also beneficial to prolong the patients′ life. Now, we are able to expect 80% 5-year survival rate in t...
[BJDITAN09]儿童HBV免疫接种
In conclusion， universal HBV vaccination provides long-term protection up to 20 years， and a universal booster is not indicated for the primary HBV vaccinees before adulthood. Mother-to-child transmission is the primary reason for vaccine failure and needs to be tackled in future vaccination program...
[BJDITAN09]HBV的遗传变异性及其临床意义
Therefore， it is necessary to monitor the occurrence and development of HBV variations and the relationship between variability and clinical outcome dynamically. Enhancing the biological characteristics research of hepatitis B virus would help us further understand the effect of mutations on viral r...
[BJDITAN09]能否预防慢性乙肝转变为肝癌？
In summary, vaccination can prevent HCC by preventing HBV infection. HBsAg clearance in an early age can almost prevent HCC. Interferon and antiviral treatment can reduce the risk but not completely prevent HCC.
[BJDITAN09]The Role of Polo-like Kinase 1 as a Therapeutic Target in Hepatocellul...
PLK1 overexpression in HCC was shown to be functionally important by gene silencing experiments, and may be a potential therapeutic target.
[BJDITAN09]肝纤维化和肝硬化的非侵袭性评估
Fibrosis is a frequent, life-threatening complication of most chronic liver diseases. Up to now liver biopsy is still the gold standard for assessment of hepatic fibrosis and cirrhosis. However, it is invasive with possible complications, costly and afflicted with a high degree of sampling error. Th...
[BJDITAN09]乙型肝炎现有药物的作用
The main role of antiviral drug therapy for chronic hepatitis B (CHB) infection is to suppress the hepatitis B virus (HBV) from active replication, thereby preventing hepatitis and the complications. Doctors and patients alike wished for achieving HBV eradication early. This will lower the risk of l...
[BJDITAN09]由抗生素耐药菌导致的特发性细菌性腹膜炎的临床意义
SBP due to antibiotic-resistant organism had higher mortality than SBP by susceptible strain and ineffective initial therapy may be a cause of the higher rates of treatment failure and mortality. Therefore, it would seem reasonable to treat patients with SBP due to antibiotic-resistant organism with...

第 1 2 页

末页